Annual And Sustainability Report

Overview

The report describes Sobi's 2019 transformation through acquisitions of Synagis, emapalumab and Dova, strengthening its Immunology and Haematology platforms. Group revenue reached SEK 14,248 M and year-end headcount was 1,377 employees. Sustainability disclosures cover access to treatment, responsible sourcing, ethics, environmental performance and employees, with reporting under GRI Core and as a UN Global Compact Communication on Progress. The report also records 95 per cent completion of employee conduct and anti-corruption training.

Document

Report type: Integrated Report
Class: Embedded
Scope: Full report
Fiscal year: 2019
Period: 1 January 2019 – 31 December 2019
Publication date: 25 March 2020
Language: English
Pages
File size
Restatement: Disclosed

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services